ReviewMicroorganisms2022
Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Veterinary macrolides againstFrontiers in veterinary science · 2026Pooled it
- Integrated Clinical Safety Assessment of Orally Administered Antimicrobials from Different Pharmacological Classes in Nile Tilapia (Animals : an open access journal from MDPI · 2026Article
- Analgesic and antioxidant potential of tulathromycin: evidence from molecular docking, in vitro assay, and in vivo model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Tylvalosin pharmacokinetics, tissue residues, and withdrawal intervals following oral and intravenous administration in geese (Anser anser domesticus), domestic pigeons (Columba livia), and Japanese quail (Coturnix japonica).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Digestate-based fertilization supports lettuce growth with limited impacts on phyllosphere bacterial communities.Frontiers in microbiology · 2026Article
- Sustainable, Targeted, and Cost-Effective Laccase-Based Bioremediation Technologies for Antibiotic Residues in the Ecosystem: A Comprehensive Review.Biomolecules · 2025Review
- Review
- Antibiotic Potentiation as a Promising Strategy to Combat Macrolide Resistance in Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model.The Journal of antibiotics · 2023Article
- Diagnosis, management and genetic analysis of a cat with primary copper hepatopathy.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolide antimicrobial agents have been in clinical use for more than 60 years in both human and veterinary medicine. The discovery of the non-antimicrobial properties of macrolides and the effect of immunomodulation of the inflammatory response has benefited patients with chronic airway diseases and impacted morbidity and mortality. This review examines the evidence of antimicrobial and non-antimicrobial properties of macrolides in human and veterinary medicine with a focus toward veterinary macrolides but including important and relevant evidence from the human literature. The complete story for these complex and important molecules is continuing to be written.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.